Abstract 850P
Background
Acute Myeloid Leukemia (AML) is the most common acute leukemia in adults. The origin can be found in chromosomal translocations as well as in accumulated mutations in genes involved in hematopoietic proliferation and differentiation. Despite being considered a heterogeneous malignancy, AML possesses many genetic aberrations, including the overexpression of MYC and the downregulation of PP2A, both essential regulators of cell proliferation, apoptosis, and differentiation, and they, directly and indirectly, regulate each other’s activity. We have generated a zebrafish model of MYC-driven AML to rapidly test the effects of different drugs in tumor development.
Methods
After the generation of a transgenic zebrafish line expressing the human MYC under the control of the neutrophils-specific promoter lysozyme (lyz:hMYC), we checked the expansion of neutrophils in whole larvae and the colonization of the adult hematopoietic organ. We investigated the effects of chemical manipulation of PP2A activity on neutrophil expansion and on MYC phosphorylation and degradation. Single-cell RNA sequencing analysis has been performed to shed light into the mechanisms of PP2A/proteasomal-mediated degradation of oncogenic MYC in AML.
Results
In vivo imaging of whole larvae revealed a robust expansion of neutrophils in zebrafish larvae which expressed MYC from 3 to 8 days post-fertilization (dpf). Surprisingly, the neutrophil number gradually returned to normal levels from 10 dpf onwards, coinciding with degradation of MYC. Pharmacological inhibition of the proteasome resulted in the stabilization of MYC protein and further expansion of transformed neutrophils. Similarly, inhibition of PP2A phenocopied the effects of proteasome inhibition. Otherwise, pharmacological activation of PP2A prevented neutrophil expansion and increased phosphorylation of S62 and T58 of MYC, suggesting a critical role PP2A in MYC proteasomal degradation.
Conclusions
Our results show that PP2A critically regulates MYC degradation in neutrophils preventing their oncogenic transformation. In addition, the zebrafish model of AML is a unique tool for chemical screening.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Murcia.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
968P - High sensitivity routine blood based detection of HCC: An AI model from 220k patients
Presenter: Kin Nam Kwok
Session: Poster session 18
969P - Establishing a novel routine blood component signature for Hepatocellular Carcinoma (HCC) screening with big clinical data
Presenter: Ka Man Cheung
Session: Poster session 18
970P - Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
Presenter: Choong-kun Lee
Session: Poster session 18
971P - Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China
Presenter: Zhongqi Fan
Session: Poster session 18
972P - Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
Presenter: Mara Persano
Session: Poster session 18
973P - Clinicopathologic and treatment outcome data in 165 fibrolamellar carcinoma patients
Presenter: Sunyoung Lee
Session: Poster session 18
974P - The barthel index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: A multicenter cohort study from China
Presenter: Guoyue Lv
Session: Poster session 18
975P - The clinical impact of urinary protein creatinine ratio and AFP at six weeks in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Presenter: Kaoru Tsuchiya
Session: Poster session 18
976P - Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic radiation therapy or systemic therapy alone
Presenter: Alexander Piening
Session: Poster session 18